COR — Cencora, Inc.

Sell-side is constructive: the Aug 5, 2026 print beat (revenue +5.1% to $84.75B; adjusted EPS $4.48 vs. $4.35 consensus), management raised the FY26 adjusted EPS range to $17.75-$17.95, Cencora bought back $1B of stock in the quarter, and the consensus rating is Buy with a $358.14 average / $365.20 recent-average target versus $321.57 on 2026-09-13. The tape disagrees with the tone: as of 2026-09-13 the stock was -2.83% over the prior week and -8.11% over six months even after a +14.17% three-month bounce, with price pinned to its 200-day average and RSI at 50.26. Investors are paying a premium P/S (0.188 vs. a 0.14 five-year average) while waiting for proof that the specialty margin mix is durable and that prior customer losses have fully cycled - hence indifferent rather than bullish.

Two distinct trends are running at once. Revenue growth has clearly decelerated: reported YoY went from +12.8% (Dec-2024 qtr), +10.3% (Mar-2025), +8.7% (Jun-2025), +5.9% (Sep-2025), +5.5% (Dec-2025), +3.9% (Mar-2026) to +5.1% in the Jun-2026 quarter ($84.75B), consistent with the maintained 4-6% FY26 revenue guide and with WAC/IRA price deflation plus prior customer losses. Meanwhile profitability is inflecting up: gross margin was 4.26% in Q3 FY26 vs. 3.30% a year earlier (+96bps), 4.24% vs. 3.47% in Q2 FY26 (+77bps), 3.27% vs. 2.78% in Q1 FY26 (+49bps), with operating margin at 1.32% vs. 1.22% YoY in the June quarter. That is a four-quarter pattern driven by specialty/services mix (OneOncology, Retina Consultants of America), not a blip. GAAP EPS is noise and should not be read as a trend: Sep-2025 carried a -$1.75 loss (net -$339.7M) on charges, Mar-2026 an $8.40 gain (net $1,641.3M) on a one-off, while adjusted EPS was $4.48 in Q3 FY26 and full-year guidance went to $17.75-$17.95 with 13-14% adjusted operating income growth. Seasonality is real - the December quarter is the working-capital drain (Q1 FY26 operating cash flow -$2.31B) and the June quarter the seasonal FCF peak (+$2.65B OCF, $2.43B FCF). Net: decelerating top line, expanding margins, low-teens adjusted EPS growth - a mix-shift story, not a broken one.

Fair, with a mild cheapness signal on cash earnings. At $321.57 on 2026-09-13 the stock is 23.79x trailing GAAP EPS of $13.59 - a meaningless figure, since that trailing window contains both a -$1.75 charge quarter and an $8.40 one-off-gain quarter - but 18.0x FY26E adjusted EPS of $17.875 and roughly 16x my ~$20 FY27E, with PEG 0.624 and a 6.5% trailing FCF yield ($4.06B TTM free cash flow). P/B of 20.4x, ROE of 103% and D/E of 3.84x are buyback artifacts (book equity is only $3.05B against $11.44B of long-term debt), not evidence of a stretched asset. The "Rich vs. its own history" tag rests mainly on P/S of 0.188 vs. a 0.14 five-year average - close to noise for a pass-through distributor whose revenue mix is shifting toward higher-priced specialty drugs - while the P/E of 23.79 is actually below the 24.41 five-year average, which itself is inflated by litigation-depressed earnings. EV/EBITDA of 13.9x is unremarkable for the sector. Verdict: fairly valued with a modest tilt toward cheap on forward earnings; not a bargain, not stretched.

The gap between the 23.8x headline TTM P/E and the 18.0x FY26E adjusted multiple is the whole game. The trailing number is inflated by a litigation-charge quarter (Sep-2025, EPS -$1.75) that has nothing to do with distribution economics; the adjusted number reflects a business compounding EPS in the low teens with negative accruals (-2.26%, i.e. cash earnings running ahead of reported income). So the market is not pricing in growth that hasn't shown up - at ~16x FY27E it is mildly discounting the durability of the margin mix shift. The catalyst is concrete: the early-to-mid-November 2026 Q4 FY26 report, where initial FY27 guidance gets set. Low-double-digit FY27 EPS growth supports fair value in the $360-380 zone; FY27 guidance at or below FY26 levels (~$17.75-$18.00) would validate the bears and likely cap the stock near the 52-week high of $377.54 rather than through it.

Range-bound and neutral as of 2026-09-13: RSI-14 at 50.26, price -0.52% vs. the 20-day (~$323), +2.04% vs. the 50-day (~$315), and +0.14% vs. the 200-day (~$321) - the three averages are compressed into a ~$315-323 band and the stock sits in the middle of it. Returns: -2.83% one week, +2.36% one month, +14.17% three months, -8.11% six months, against a 52-week range of $244.82-$377.54 (price roughly 15% below the high, 31% above the low). Read: the rebound off the spring lows has stalled into consolidation right at the 200-day, with nothing overbought or oversold. Timing implication: no urgency to chase. Holding above ~$315 keeps the base intact; a decisive break below ~$310 would say the three-month bounce failed, while a close above ~$325-330 on volume sets up a retest of the upper end of the 52-week range.

• GLP-1 and specialty/oncology volume growth: richer mix is the main reason gross margin rose roughly 50-95bps YoY, and it is what levers a 1.3% operating margin into double-digit profit growth.
• Drug price deflation: IRA Medicare negotiation, WAC reductions and brand-to-generic conversion hold reported revenue growth in the 4-6% range even as unit volumes rise - the reason revenue decelerated while profit accelerated.
• Interest rates and refinancing: $11.44B of long-term debt against $3.05B of book equity means interest expense and refinancing spreads flow straight into a 1.3%-margin P&L; lower rates are a genuine tailwind, higher-for-longer is a real drag.
• Healthcare policy risk: PBM reform, 340B changes and any legislation altering how distributors are compensated for specialty volumes can reprice the channel quickly.
• Defensive rotation and trade policy: beta of 0.574 makes COR behave like a bond proxy - it lags in strong risk-on tape and outperforms in drawdowns - while tariff/trade policy on pharmaceutical imports is a wildcard for both cost of goods and inventory timing.

• Q4 FY26 results and initial FY27 guidance in early-to-mid November 2026 - the single biggest near-term event; FY26 adjusted EPS is guided to $17.75-$17.95 on 13-14% adjusted operating income growth.
• Continued capital return: $1B of buybacks in the June-2026 quarter alone, plus dividend growth, mechanically lifts EPS and supports the multiple.
• Specialty platform build-out (OneOncology, Retina Consultants of America) and commercial ramp of the Cell & Gene Therapy Enablement service launched Sept 2, 2026 - small today, but higher-margin than core distribution.
• Another quarter of ~50-90bps gross-margin expansion would validate the re-rating case; conversely, a stall would undercut it.
• Clarity on large customer contract renewals and the tail of prior customer losses that have been capping reported revenue growth.

• Structural margin thinness: 1.3% operating and 0.8% net margin means a modest mix or pricing reversal (mail-order brand conversion, GLP-1 margin pressure) swings EPS hard; the model's low score on margin level is not wrong about that fragility.
• Working-capital volatility: quarterly operating cash flow swung from -$2.31B (Dec-2025) to +$2.65B (Jun-2026); one bad inventory/payables quarter can flip the free-cash-flow narrative.
• Balance-sheet optics: $3.05B equity vs. $11.44B long-term debt (D/E 3.84x), current ratio 0.935, quick ratio 0.58 - normal for the model but it means the refinancing lever sits with credit markets, and continued buybacks keep shrinking the cushion.
• GAAP earnings noise: the last four quarters include a -$1.75 EPS charge quarter and an $8.40 EPS one-off quarter, so headline P/E and any mechanical screen will keep mispricing the stock in both directions.
• Regulatory and legal drag: IRA price cuts, WAC deflation and residual opioid-litigation payments recur as both cash costs and headline risk.
• Revenue growth deceleration from ~13% YoY to ~4-5%: if it settles at the low end while margin expansion stalls, the low-teens EPS growth case breaks.

At $321.57 on 2026-09-13 you are paying 18.0x FY26E adjusted EPS and about 16x FY27E for a defensive, negative-accrual, 13.2% ROIC distributor with a 6.5% free-cash-flow yield and a 0.57 beta - a reasonable if unexciting risk/reward for defense-and-income money. It is not a screaming value: revenue growth has slid to mid-single digits, operating margins are structurally 1.3%, and the balance sheet is thin where mechanical credit screens look. Own it as a steady compounding hedge, not an upside vehicle, and treat the November 2026 FY27 guide as the point where the thesis gets re-scored.

18.5x my FY27E adjusted EPS of ~$20.00 (the $17.85 FY26 guidance midpoint grown ~12%, consistent with the 13-14% adjusted operating income growth guide), a multiple set below the distorted 24.4x five-year average TTM P/E and at a modest discount to larger distribution peers to reflect 1.3% operating margins, mid-single-digit revenue growth and thin book equity; cross-checked by ~14x EV/EBITDA on ~$5.7B FY27E EBITDA less ~$8.9B net debt and by the 6.5% trailing FCF yield, both of which land near $366-372.